Drug intelligence / Profile preview

SAGE-817

Development stage: Preclinical
Lead developer: Sage Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SAGE-817 is an investigational orally administered NMDA receptor negative allosteric modulator (NAM) developed by Sage Therapeutics. It targets glutamate signaling, a pathway implicated in neurodevelopmental disorders, schizophrenia, depression, and neurodegenerative diseases. The drug is designed to offer similar or better efficacy than existing NMDA receptor blockers like ketamine but with potentially improved safety and tolerability profiles. SAGE-817 inhibits a broad array of NMDA receptor subtypes and is currently in preclinical development for neurodevelopmental disorders[2][4][5].

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on SAGE-817.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAGE-817.

Explore the full profile